Background: Various HDAC inhibitors were described as beneficially affecting anti-tumoral immune
response. Although different HDAC inhibitors have been investigated in syngeneic tumor
models, the mode of anti-tumoral action is not yet fully understood. Here, we analyzed
the anti-tumoral mode-of-action of 4SC-202, an orally available clinical stage epigenetic
small molecule inhibitor targeting histone deacetylases (HDAC) class I. We used a
clinically equivalent dosage regimen to ensure that the results would be relevant
for the clinical situation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P05.02
Identification
Copyright
© 2018 Published by Elsevier Inc.
